Skip to main content

Advertisement

SpringerLink
Log in

Prevention and Management of HBV Infection in Patients with Chronic Kidney Disease Requiring Renal Transplantation

  • Hepatitis B (J Lim, Section Editor)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

This review addresses clinical challenges of hepatitis B virus (HBV) infection in patients with chronic kidney disease and renal transplant recipients.

Recent Findings

Prophylactic antiviral therapy with nucleos(t)ide analogues is key to prevent HBV reactivation in renal transplant recipients. In addition, attaining adequate immunity following vaccination against HBV may permit transplantation of renal grafts from donors with evidence of prior HBV infection. The role of nucleos(t)ide analogues for treatment of recurrent or de novo HBV infection in renal transplant recipients is well established and preliminary experience demonstrate significant reductions in the median time in the renal transplant waiting list by transplanting HBsAg-positive renal grafts into HBsAg-positive recipients, without sacrificing graft or patient survival with the use of these agents.

Summary

Availability of potent nucleos(t)ide analogues results in improved outcomes following renal transplantation in patients with chronic HBV infection by avoiding recurrent or de novo infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.

    CAS  PubMed  Google Scholar 

  2. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol. 2000;20(1):1–11.

    CAS  PubMed  Google Scholar 

  3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.

    PubMed  Google Scholar 

  4. Garcia Agudo R, Aoufi Rabih S, Barril Cuadrado G, et al. Spanish multicentre PIBHE study: prevalence and immunization of chronic hepatitis B in haemodialysis patients in Spain. Nefrologia. 2016;36(2):126–32.

    PubMed  Google Scholar 

  5. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003;63(6):2222–9.

    PubMed  Google Scholar 

  6. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009;24(5):1598–603.

    PubMed  Google Scholar 

  7. Fabrizi F, Martin P, Messa P. Hepatitis B and hepatitis C virus and chronic kidney disease. Acta Gastro-Enterol Belg. 2010;73(4):465–71.

    CAS  Google Scholar 

  8. Tseng GY, Lin HJ, Fang CT, Cheng YT, Huang CH, Tseng GC, et al. Hemodialysis reduces the viral load in uremic patients with chronic hepatitis B infection. Ren Fail. 2008;30(10):1000–5.

    CAS  PubMed  Google Scholar 

  9. Martin P, Friedman LS. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int. 1995;47(5):1231–41.

    CAS  PubMed  Google Scholar 

  10. Fabrizi F, Martin P, Messa P. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs. 2015;38(12):625–31.

    PubMed  Google Scholar 

  11. Ow MM, de Zoysa JR, Gane EJ. The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis. N Z Med J. 2014;127(1396):34–42.

    PubMed  Google Scholar 

  12. Degos F, Lugassy C, Degott C, Debure A, Carnot F, Thiers V, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology. 1988;94(1):151–6.

    CAS  PubMed  Google Scholar 

  13. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2005;5(12):2913–21.

    CAS  Google Scholar 

  14. Reddy PN, Sampaio MS, Kuo HT, Martin P, Bunnapradist S. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol. 2011;6(6):1481–7.

    PubMed  PubMed Central  Google Scholar 

  15. Rangel MC, Coronado VG, Euler GL, et al. Vaccine recommendations for patients on chronic dialysis. The advisory committee on immunization practices and the American Academy of Pediatrics. Semin Dial. 2000;13(2):101–7.

    CAS  PubMed  Google Scholar 

  16. Janssen JM, Heyward WL, Martin JT, Janssen RS. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Vaccine. 2015;33(7):833–7.

    CAS  PubMed  Google Scholar 

  17. • Zitt E, Hafner-Giessauf H, Wimmer B, et al. Response to active hepatitis B vaccination and mortality in incident dialysis patients. Vaccine. 2017;35(5):814–20 Retrospective cohort study suggesting signifcant recuction in all cause mortality associated with HBV vaccination of patients with CKD undergoing dialysis.

    PubMed  Google Scholar 

  18. He WY, Jin YJ, Wang WP, Li CL, Ji ZB, Yang C. Tissue elasticity quantification by acoustic radiation force impulse for the assessment of renal allograft function. Ultrasound Med Biol. 2014;40(2):322–9.

    PubMed  Google Scholar 

  19. Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, et al. Does this patient with liver disease have cirrhosis? Jama. 2012;307(8):832–42.

    CAS  PubMed  Google Scholar 

  20. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation. 2005;80(11):1550–5.

    PubMed  Google Scholar 

  21. Chopra A, Cantarovich M, Bain VG. Simultaneous liver and kidney transplants: optimizing use of this double resource. Transplantation. 2011;91(12):1305–9.

    PubMed  Google Scholar 

  22. • European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85 European guidelines for diagnosis and management of HBV infection in the general population and special populations.

    Google Scholar 

  23. Duhart BT Jr, Honaker MR, Shokouh-Amiri MH, Riely CA, Vera SR, Taylor SL, et al. Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. Transpl Infect Dis. 2003;5(3):126–31.

    PubMed  Google Scholar 

  24. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 2005;16(6):1758–74.

    PubMed  Google Scholar 

  25. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13(1):150–7.

    CAS  PubMed  Google Scholar 

  26. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703–11.

    PubMed  PubMed Central  Google Scholar 

  27. • Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83 American guidelines for diagnosis and management of HBV infection in the general population and special populations.

    PubMed  Google Scholar 

  28. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–15.

    CAS  PubMed  Google Scholar 

  29. Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32(3):434–9.

    CAS  PubMed  Google Scholar 

  30. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–244 e223.

    PubMed  Google Scholar 

  31. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation. 1995;59(2):230–4.

    CAS  PubMed  Google Scholar 

  32. Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage. J Nephrol. 2002;15(6):605–13.

    PubMed  Google Scholar 

  33. Fong TL, Bunnapradist S, Jordan SC, Cho YW. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of united network of organ sharing database between 1994 and 1999. Transplantation. 2002;73(1):85–9.

    PubMed  Google Scholar 

  34. Pilmore HL, Gane EJ. Hepatitis B-positive donors in renal transplantation: increasing the deceased donor pool. Transplantation. 2012;94(3):205–10.

    CAS  PubMed  Google Scholar 

  35. Veroux M, Corona D, Ekser B, Giaquinta A, Tallarita T, de Martino C, et al. Kidney transplantation from hepatitis B virus core antibody-positive donors: prophylaxis with hepatitis B immunoglobulin. Transplant Proc. 2011;43(4):967–70.

    CAS  PubMed  Google Scholar 

  36. • Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15(5):1162–72 Consensus guidelines summarizing current evidence-based management of solid-organ transplant recipients of grafts (including renal) from HBV-positive donors.

    CAS  PubMed  Google Scholar 

  37. Veroux M, Puliatti C, Macarone M, Cappello D, Gagliano M, Spataro M, et al. Kidney transplantation from hepatitis B surface antigen-positive donors into hepatitis B surface antigen-positive recipients: preliminary findings. Transplant Proc. 2005;37(6):2467–8.

    CAS  PubMed  Google Scholar 

  38. Stock PG. A source of treatment for those who were (almost) lost: human immunodeficiency virus-positive to human immunodeficiency virus-positive kidney transplantation-results at 3 to 5 years. Transplantation. 2015;99(9):1744–5.

    PubMed  Google Scholar 

  39. Jiang H, Wu J, Zhang X, Wu D, Huang H, He Q, et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2009;9(8):1853–8.

    CAS  Google Scholar 

  40. Singh G, Hsia-Lin A, Skiest D, Germain M, O'Shea M, Braden G. Successful kidney transplantation from a hepatitis B surface antigen-positive donor to an antigen-negative recipient using a novel vaccination regimen. Am J Kidney Dis. 2013;61(4):608–11.

    CAS  PubMed  Google Scholar 

  41. • Chancharoenthana W, Townamchai N, Pongpirul K, et al. The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study. Am J Transplant. 2014;14(12):2814–20 Retrospective study showing good outcomes and no HBV transmision following renal transplantation of renal grafts from HBsAg-positive donors without viremia into HBsAg-negative reciepients with documented immunity (anti-HBs).

    CAS  PubMed  Google Scholar 

  42. Tuncer M, Tekin S, Yucetin L, et al. Hepatitis B surface antigen positivity is not a contraindication for living kidney donation. Transplant Proc. 2012;44(6):1628–9.

    CAS  PubMed  Google Scholar 

  43. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine. 2005;84(5):313–22.

    PubMed  Google Scholar 

  44. Zhang Y, Zhou JH, Yin XL, et al. Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis. World J Gastroenterol. 2010;16(6):770–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Wang WN, Wu MY, Ma FZ, et al. Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis. Clin Nephrol. 2016;85(1):21–9.

    CAS  PubMed  Google Scholar 

  46. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006;24(5):781–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Miami Miller School of Medicine, 1120 NW 14th Street, Office 189, Miami, FL, 33136, USA

    Andres F. Carrion

  2. University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA

    Paul Martin

Authors
  1. Andres F. Carrion
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andres F. Carrion.

Ethics declarations

Conflicts of Interest

Andres F. Carrion reports personal fees from Gilead, personal fees from BMS, during the conduct of the study. Paul Martin reports grants and personal fees from Gilead, grants and personal fees from BMS, during the conduct of the study.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hepatitis B

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carrion, A.F., Martin, P. Prevention and Management of HBV Infection in Patients with Chronic Kidney Disease Requiring Renal Transplantation. Curr Hepatology Rep 17, 485–491 (2018). https://doi.org/10.1007/s11901-018-0438-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-018-0438-2

Keywords

Search

Navigation